PMC:7228307 / 42876-46017
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
---|---|---|---|---|---|---|
793 | 232-258 | Gene | denotes | Matrix Metalloproteinase 9 | Gene:4318 | |
794 | 260-264 | Gene | denotes | MMP9 | Gene:4318 | |
795 | 642-649 | Gene | denotes | FcγRIII | Gene:2214 | |
796 | 1067-1074 | Gene | denotes | FcγRIII | Gene:2214 | |
797 | 1271-1275 | Gene | denotes | HER2 | Gene:2064 | |
798 | 1338-1345 | Gene | denotes | FcγRIII | Gene:2214 | |
799 | 1394-1423 | Gene | denotes | C–C chemokine receptor type 4 | Gene:1233 | |
800 | 1425-1429 | Gene | denotes | CCR4 | Gene:1233 | |
801 | 1472-1479 | Gene | denotes | FcγRIII | Gene:2214 | |
802 | 1614-1621 | Gene | denotes | FcγRIII | Gene:2214 | |
803 | 1666-1670 | Gene | denotes | PD‐1 | Gene:5133 | |
804 | 1806-1813 | Gene | denotes | FcγRIII | Gene:2214 | |
805 | 1918-1925 | Gene | denotes | FcγRIII | Gene:2214 | |
806 | 1974-1978 | Gene | denotes | PD‐1 | Gene:5133 | |
807 | 2106-2113 | Gene | denotes | FcγRIII | Gene:2214 | |
808 | 2726-2733 | Gene | denotes | FcγRIII | Gene:2214 | |
809 | 2523-2527 | Gene | denotes | FcγR | Gene:2213 | |
810 | 2498-2502 | Gene | denotes | FcγR | Gene:2213 | |
811 | 2319-2323 | Gene | denotes | FcγR | Gene:2213 | |
812 | 2221-2225 | Gene | denotes | FcγR | Gene:2213 | |
813 | 864-868 | Gene | denotes | FcγR | Gene:2213 | |
814 | 540-544 | Gene | denotes | FcγR | Gene:2213 | |
815 | 447-451 | Gene | denotes | FcγR | Gene:2213 | |
816 | 2606-2610 | Gene | denotes | PD‐1 | Gene:5133 | |
817 | 2377-2381 | Gene | denotes | PD‐1 | Gene:5133 | |
818 | 779-784 | Gene | denotes | PD‐L1 | Gene:29126 | |
819 | 497-502 | Gene | denotes | PD‐L1 | Gene:29126 | |
820 | 688-713 | Disease | denotes | ear nose throat disorders | MESH:D004427 | |
821 | 976-995 | Disease | denotes | Metabolic disorders | MESH:D008659 | |
822 | 1221-1246 | Disease | denotes | musculoskeletal disorders | MESH:D009140 | |
823 | 1707-1725 | Disease | denotes | Infectious disease | MESH:D003141 | |
824 | 2015-2024 | Disease | denotes | Infection | MESH:D007239 | |
825 | 2127-2150 | Disease | denotes | Hematological disorders | MESH:D006402 | |
826 | 2333-2352 | Disease | denotes | Metabolic disorders | MESH:D008659 | |
827 | 2618-2623 | Mutation | denotes | S228P | rs1469294455 | |
828 | 792-797 | Mutation | denotes | L234F | p.L234F | |
829 | 799-804 | Mutation | denotes | L235E | p.L235E | |
830 | 806-811 | Mutation | denotes | P331S | p.P331S | |
831 | 525-530 | Mutation | denotes | N297A | p.N297A | |
832 | 375-380 | Mutation | denotes | L234F | p.L234F | |
833 | 382-387 | Mutation | denotes | L235E | p.L235E | |
834 | 389-394 | Mutation | denotes | P331S | p.P331S | |
835 | 2389-2394 | Mutation | denotes | S228P | rs1469294455 | |
836 | 1986-1991 | Mutation | denotes | S228P | rs1469294455 | |
837 | 1283-1288 | Mutation | denotes | F243L | p.F243L | |
838 | 1290-1295 | Mutation | denotes | L235V | p.L235V | |
839 | 1297-1302 | Mutation | denotes | R292P | p.R292P | |
840 | 1304-1309 | Mutation | denotes | Y300L | p.Y300L | |
841 | 1311-1316 | Mutation | denotes | P396L | p.P396L | |
842 | 1580-1585 | Mutation | denotes | S239D | p.S239D | |
843 | 1587-1592 | Mutation | denotes | I332E | p.I332E | |
844 | 1678-1683 | Mutation | denotes | S228P | rs1469294455 | |
845 | 1884-1889 | Mutation | denotes | P247I | p.P247I | |
846 | 1891-1896 | Mutation | denotes | A339Q | p.A339Q | |
847 | 1167-1172 | Mutation | denotes | S228P | rs1469294455 | |
848 | 2298-2303 | Mutation | denotes | L234A | p.L234A | |
849 | 2410-2415 | Mutation | denotes | L235A | p.L235A | |
850 | 2200-2205 | Mutation | denotes | L234A | p.L234A | |
851 | 2305-2310 | Mutation | denotes | L235A | p.L235A | |
852 | 947-952 | Mutation | denotes | S228P | rs1469294455 | |
853 | 2396-2401 | Mutation | denotes | E233P | p.E233P | |
854 | 2403-2408 | Mutation | denotes | F234V | rs755807976 | |
855 | 2207-2212 | Mutation | denotes | L235A | p.L235A | |
856 | 2417-2422 | Mutation | denotes | D265A | p.D265A | |
857 | 2424-2429 | Mutation | denotes | L309V | p.L309V | |
858 | 2431-2436 | Mutation | denotes | R409K | p.R409K | |
859 | 273-278 | Mutation | denotes | S228P | rs1469294455 | |
861 | 2916-2924 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T361 | 125-128 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T362 | 129-137 | Body_part | denotes | backbone | http://purl.org/sig/ont/fma/fma13478 |
T363 | 587-600 | Body_part | denotes | Interleukin 5 | http://purl.org/sig/ont/fma/fma264830 |
T364 | 587-598 | Body_part | denotes | Interleukin | http://purl.org/sig/ont/fma/fma86578 |
T365 | 688-691 | Body_part | denotes | ear | http://purl.org/sig/ont/fma/fma52780 |
T366 | 692-696 | Body_part | denotes | nose | http://purl.org/sig/ont/fma/fma46472 |
T367 | 697-703 | Body_part | denotes | throat | http://purl.org/sig/ont/fma/fma228738 |
T368 | 930-937 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T369 | 1088-1110 | Body_part | denotes | Central nervous system | http://purl.org/sig/ont/fma/fma55675 |
T370 | 1144-1155 | Body_part | denotes | Interleukin | http://purl.org/sig/ont/fma/fma86578 |
T371 | 1398-1407 | Body_part | denotes | chemokine | http://purl.org/sig/ont/fma/fma241981 |
T372 | 1493-1515 | Body_part | denotes | Central nervous system | http://purl.org/sig/ont/fma/fma55675 |
T373 | 2747-2769 | Body_part | denotes | Central nervous system | http://purl.org/sig/ont/fma/fma55675 |
T374 | 2791-2793 | Body_part | denotes | Ig | http://purl.org/sig/ont/fma/fma62871 |
T375 | 2795-2809 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T22 | 688-691 | Body_part | denotes | ear | http://purl.obolibrary.org/obo/UBERON_0001690 |
T23 | 692-696 | Body_part | denotes | nose | http://purl.obolibrary.org/obo/UBERON_0000004 |
T24 | 697-703 | Body_part | denotes | throat | http://purl.obolibrary.org/obo/UBERON_0000341 |
T25 | 1088-1110 | Body_part | denotes | Central nervous system | http://purl.obolibrary.org/obo/UBERON_0001017 |
T26 | 1096-1110 | Body_part | denotes | nervous system | http://purl.obolibrary.org/obo/UBERON_0001016 |
T27 | 1493-1515 | Body_part | denotes | Central nervous system | http://purl.obolibrary.org/obo/UBERON_0001017 |
T28 | 1501-1515 | Body_part | denotes | nervous system | http://purl.obolibrary.org/obo/UBERON_0001016 |
T29 | 2747-2769 | Body_part | denotes | Central nervous system | http://purl.obolibrary.org/obo/UBERON_0001017 |
T30 | 2755-2769 | Body_part | denotes | nervous system | http://purl.obolibrary.org/obo/UBERON_0001016 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T71 | 688-713 | Disease | denotes | ear nose throat disorders | http://purl.obolibrary.org/obo/MONDO_0024623 |
T72 | 976-995 | Disease | denotes | Metabolic disorders | http://purl.obolibrary.org/obo/MONDO_0005066 |
T73 | 1221-1246 | Disease | denotes | musculoskeletal disorders | http://purl.obolibrary.org/obo/MONDO_0002081 |
T74 | 1707-1725 | Disease | denotes | Infectious disease | http://purl.obolibrary.org/obo/MONDO_0005550 |
T75 | 2015-2024 | Disease | denotes | Infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T76 | 2127-2150 | Disease | denotes | Hematological disorders | http://purl.obolibrary.org/obo/MONDO_0005570 |
T77 | 2333-2352 | Disease | denotes | Metabolic disorders | http://purl.obolibrary.org/obo/MONDO_0005066 |
T78 | 2916-2924 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T767 | 9-11 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T768 | 139-141 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T769 | 447-449 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T770 | 497-502 | http://purl.obolibrary.org/obo/CLO_0008407 | denotes | PD‐L1 |
T771 | 540-542 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T772 | 642-644 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T773 | 688-691 | http://www.ebi.ac.uk/efo/EFO_0000826 | denotes | ear |
T774 | 692-696 | http://www.ebi.ac.uk/efo/EFO_0000828 | denotes | nose |
T775 | 779-784 | http://purl.obolibrary.org/obo/CLO_0008407 | denotes | PD‐L1 |
T776 | 864-866 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T777 | 1021-1025 | http://purl.obolibrary.org/obo/CLO_0053432 | denotes | CD19 |
T778 | 1067-1069 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T779 | 1088-1110 | http://purl.obolibrary.org/obo/UBERON_0001017 | denotes | Central nervous system |
T780 | 1088-1110 | http://www.ebi.ac.uk/efo/EFO_0000302 | denotes | Central nervous system |
T781 | 1088-1110 | http://www.ebi.ac.uk/efo/EFO_0000908 | denotes | Central nervous system |
T782 | 1338-1340 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T783 | 1472-1474 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T784 | 1493-1515 | http://purl.obolibrary.org/obo/UBERON_0001017 | denotes | Central nervous system |
T785 | 1493-1515 | http://www.ebi.ac.uk/efo/EFO_0000302 | denotes | Central nervous system |
T786 | 1493-1515 | http://www.ebi.ac.uk/efo/EFO_0000908 | denotes | Central nervous system |
T787 | 1568-1572 | http://purl.obolibrary.org/obo/CLO_0053432 | denotes | CD19 |
T788 | 1614-1616 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T789 | 1806-1808 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T790 | 1918-1920 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T791 | 2106-2108 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T792 | 2221-2223 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T793 | 2287-2290 | http://purl.obolibrary.org/obo/CLO_0052882 | denotes | CD3 |
T794 | 2287-2290 | http://purl.obolibrary.org/obo/CLO_0053434 | denotes | CD3 |
T795 | 2319-2321 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T796 | 2498-2500 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T797 | 2523-2525 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T798 | 2726-2728 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T799 | 2747-2769 | http://purl.obolibrary.org/obo/UBERON_0001017 | denotes | Central nervous system |
T800 | 2747-2769 | http://www.ebi.ac.uk/efo/EFO_0000302 | denotes | Central nervous system |
T801 | 2747-2769 | http://www.ebi.ac.uk/efo/EFO_0000908 | denotes | Central nervous system |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T222 | 346-351 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
T223 | 352-356 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T224 | 497-499 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T225 | 779-781 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T226 | 930-937 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T227 | 1666-1668 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T228 | 1959-1972 | Chemical | denotes | Pembrolizumab | http://purl.obolibrary.org/obo/CHEBI_82976 |
T229 | 1974-1976 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T230 | 2186-2188 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T232 | 2360-2362 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T233 | 2377-2379 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T234 | 2606-2608 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T18 | 2791-2793 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | Ig | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
T19 | 2795-2809 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T213 | 704-713 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
T214 | 986-995 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
T215 | 1237-1246 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
T216 | 1707-1725 | http://purl.obolibrary.org/obo/IDO_0000436 | denotes | Infectious disease |
T217 | 1718-1725 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
T218 | 2015-2024 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | Infection |
T219 | 2141-2150 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
T220 | 2343-2352 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T47 | 930-937 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
---|---|---|---|---|---|---|
793 | 232-258 | Gene | denotes | Matrix Metalloproteinase 9 | Gene:4318 | |
794 | 260-264 | Gene | denotes | MMP9 | Gene:4318 | |
795 | 642-649 | Gene | denotes | FcγRIII | Gene:2214 | |
796 | 1067-1074 | Gene | denotes | FcγRIII | Gene:2214 | |
798 | 1338-1345 | Gene | denotes | FcγRIII | Gene:2214 | |
799 | 1394-1423 | Gene | denotes | C–C chemokine receptor type 4 | Gene:1233 | |
800 | 1425-1429 | Gene | denotes | CCR4 | Gene:1233 | |
801 | 1472-1479 | Gene | denotes | FcγRIII | Gene:2214 | |
802 | 1614-1621 | Gene | denotes | FcγRIII | Gene:2214 | |
803 | 1666-1670 | Gene | denotes | PD‐1 | Gene:5133 | |
804 | 1806-1813 | Gene | denotes | FcγRIII | Gene:2214 | |
805 | 1918-1925 | Gene | denotes | FcγRIII | Gene:2214 | |
806 | 1974-1978 | Gene | denotes | PD‐1 | Gene:5133 | |
807 | 2106-2113 | Gene | denotes | FcγRIII | Gene:2214 | |
808 | 2726-2733 | Gene | denotes | FcγRIII | Gene:2214 | |
809 | 2523-2527 | Gene | denotes | FcγR | Gene:2213 | |
810 | 2498-2502 | Gene | denotes | FcγR | Gene:2213 | |
811 | 2319-2323 | Gene | denotes | FcγR | Gene:2213 | |
812 | 2221-2225 | Gene | denotes | FcγR | Gene:2213 | |
813 | 864-868 | Gene | denotes | FcγR | Gene:2213 | |
814 | 540-544 | Gene | denotes | FcγR | Gene:2213 | |
815 | 447-451 | Gene | denotes | FcγR | Gene:2213 | |
816 | 2606-2610 | Gene | denotes | PD‐1 | Gene:5133 | |
817 | 2377-2381 | Gene | denotes | PD‐1 | Gene:5133 | |
818 | 779-784 | Gene | denotes | PD‐L1 | Gene:29126 | |
819 | 497-502 | Gene | denotes | PD‐L1 | Gene:29126 | |
820 | 688-713 | Disease | denotes | ear nose throat disorders | MESH:D004427 | |
821 | 976-995 | Disease | denotes | Metabolic disorders | MESH:D008659 | |
822 | 1221-1246 | Disease | denotes | musculoskeletal disorders | MESH:D009140 | |
823 | 1707-1725 | Disease | denotes | Infectious disease | MESH:D003141 | |
824 | 2015-2024 | Disease | denotes | Infection | MESH:D007239 | |
825 | 2127-2150 | Disease | denotes | Hematological disorders | MESH:D006402 | |
826 | 2333-2352 | Disease | denotes | Metabolic disorders | MESH:D008659 | |
827 | 2618-2623 | Mutation | denotes | S228P | rs1469294455 | |
828 | 792-797 | Mutation | denotes | L234F | p.L234F | |
829 | 799-804 | Mutation | denotes | L235E | p.L235E | |
830 | 806-811 | Mutation | denotes | P331S | p.P331S | |
831 | 525-530 | Mutation | denotes | N297A | p.N297A | |
832 | 375-380 | Mutation | denotes | L234F | p.L234F | |
833 | 382-387 | Mutation | denotes | L235E | p.L235E | |
834 | 389-394 | Mutation | denotes | P331S | p.P331S | |
835 | 2389-2394 | Mutation | denotes | S228P | rs1469294455 | |
836 | 1986-1991 | Mutation | denotes | S228P | rs1469294455 | |
837 | 1283-1288 | Mutation | denotes | F243L | p.F243L | |
838 | 1290-1295 | Mutation | denotes | L235V | p.L235V | |
839 | 1297-1302 | Mutation | denotes | R292P | p.R292P | |
840 | 1304-1309 | Mutation | denotes | Y300L | p.Y300L | |
841 | 1311-1316 | Mutation | denotes | P396L | p.P396L | |
842 | 1580-1585 | Mutation | denotes | S239D | p.S239D | |
843 | 1587-1592 | Mutation | denotes | I332E | p.I332E | |
844 | 1678-1683 | Mutation | denotes | S228P | rs1469294455 | |
845 | 1884-1889 | Mutation | denotes | P247I | p.P247I | |
846 | 1891-1896 | Mutation | denotes | A339Q | p.A339Q | |
848 | 2298-2303 | Mutation | denotes | L234A | p.L234A | |
849 | 2410-2415 | Mutation | denotes | L235A | p.L235A | |
850 | 2200-2205 | Mutation | denotes | L234A | p.L234A | |
851 | 2305-2310 | Mutation | denotes | L235A | p.L235A | |
853 | 2396-2401 | Mutation | denotes | E233P | p.E233P | |
854 | 2403-2408 | Mutation | denotes | F234V | rs755807976 | |
855 | 2207-2212 | Mutation | denotes | L235A | p.L235A | |
856 | 2417-2422 | Mutation | denotes | D265A | p.D265A | |
857 | 2424-2429 | Mutation | denotes | L309V | p.L309V | |
858 | 2431-2436 | Mutation | denotes | R409K | p.R409K |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T43 | 2916-2924 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T242 | 0-106 | Sentence | denotes | Table 4 Fc or hinge‐engineered monoclonal antibodies (mAbs) approved or in advanced clinical development. |
T243 | 107-216 | Sentence | denotes | mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage |
T244 | 217-321 | Sentence | denotes | Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III |
T245 | 322-482 | Sentence | denotes | Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III |
T246 | 483-572 | Sentence | denotes | Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed |
T247 | 573-766 | Sentence | denotes | Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed |
T248 | 767-896 | Sentence | denotes | Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed |
T249 | 897-1006 | Sentence | denotes | Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III |
T250 | 1007-1131 | Sentence | denotes | Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III |
T251 | 1132-1256 | Sentence | denotes | Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed |
T252 | 1257-1378 | Sentence | denotes | Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III |
T253 | 1379-1535 | Sentence | denotes | Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed |
T254 | 1536-1654 | Sentence | denotes | Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III |
T255 | 1655-1745 | Sentence | denotes | Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed |
T256 | 1746-1857 | Sentence | denotes | Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed |
T257 | 1858-1958 | Sentence | denotes | Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III |
T258 | 1959-2044 | Sentence | denotes | Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed |
T259 | 2045-2161 | Sentence | denotes | Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III |
T260 | 2162-2274 | Sentence | denotes | Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III |
T261 | 2275-2362 | Sentence | denotes | Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II |
T262 | 2363-2583 | Sentence | denotes | Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III |
T263 | 2584-2666 | Sentence | denotes | Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III |
T264 | 2667-2790 | Sentence | denotes | Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III |
T265 | 2791-2810 | Sentence | denotes | Ig, immunoglobulin. |
T266 | 2811-2958 | Sentence | denotes | John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. |
T267 | 2959-3141 | Sentence | denotes | It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
LitCovid-sample-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T22 | 688-691 | Body_part | denotes | ear | http://purl.obolibrary.org/obo/UBERON_0001690 |
T23 | 692-696 | Body_part | denotes | nose | http://purl.obolibrary.org/obo/UBERON_0000004 |
T24 | 697-703 | Body_part | denotes | throat | http://purl.obolibrary.org/obo/UBERON_0000341 |
T25 | 1088-1110 | Body_part | denotes | Central nervous system | http://purl.obolibrary.org/obo/UBERON_0001017 |
T26 | 1493-1515 | Body_part | denotes | Central nervous system | http://purl.obolibrary.org/obo/UBERON_0001017 |
T27 | 2747-2769 | Body_part | denotes | Central nervous system | http://purl.obolibrary.org/obo/UBERON_0001017 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T393 | 232-258 | Protein | denotes | Matrix Metalloproteinase 9 | https://www.uniprot.org/uniprot/Q9UDK2|https://www.uniprot.org/uniprot/Q9UCL1|https://www.uniprot.org/uniprot/Q9UCJ9|https://www.uniprot.org/uniprot/Q9H4Z1|https://www.uniprot.org/uniprot/Q9DC02|https://www.uniprot.org/uniprot/Q8N725|https://www.uniprot.org/uniprot/Q80XI8|https://www.uniprot.org/uniprot/Q3LR70|https://www.uniprot.org/uniprot/Q06788|https://www.uniprot.org/uniprot/P52176|https://www.uniprot.org/uniprot/P50282|https://www.uniprot.org/uniprot/P41246|https://www.uniprot.org/uniprot/P41245|https://www.uniprot.org/uniprot/P14780|https://www.uniprot.org/uniprot/O19130|https://www.uniprot.org/uniprot/O18733|https://www.uniprot.org/uniprot/B2R7V9|https://www.uniprot.org/uniprot/A5PKB8 |
T411 | 260-264 | Protein | denotes | MMP9 | https://www.uniprot.org/uniprot/Q9UDK2|https://www.uniprot.org/uniprot/Q9UCL1|https://www.uniprot.org/uniprot/Q9UCJ9|https://www.uniprot.org/uniprot/Q9H4Z1|https://www.uniprot.org/uniprot/Q9DC02|https://www.uniprot.org/uniprot/Q8N725|https://www.uniprot.org/uniprot/Q80XI8|https://www.uniprot.org/uniprot/Q3LR70|https://www.uniprot.org/uniprot/Q06788|https://www.uniprot.org/uniprot/P52176|https://www.uniprot.org/uniprot/P50282|https://www.uniprot.org/uniprot/P41246|https://www.uniprot.org/uniprot/P41245|https://www.uniprot.org/uniprot/P14780|https://www.uniprot.org/uniprot/O19130|https://www.uniprot.org/uniprot/O18733|https://www.uniprot.org/uniprot/B2R7V9|https://www.uniprot.org/uniprot/A5PKB8 |
T429 | 335-367 | Protein | denotes | Interferon alpha/beta receptor 1 | https://www.uniprot.org/uniprot/Q95206|https://www.uniprot.org/uniprot/Q8WTZ2|https://www.uniprot.org/uniprot/Q80UJ3|https://www.uniprot.org/uniprot/Q7M4L2|https://www.uniprot.org/uniprot/Q764M8|https://www.uniprot.org/uniprot/Q6PKD7|https://www.uniprot.org/uniprot/Q53H11|https://www.uniprot.org/uniprot/Q53GW9|https://www.uniprot.org/uniprot/Q28589|https://www.uniprot.org/uniprot/Q04790|https://www.uniprot.org/uniprot/P33896|https://www.uniprot.org/uniprot/P17181|https://www.uniprot.org/uniprot/D3DSF0|https://www.uniprot.org/uniprot/B4DNT3|https://www.uniprot.org/uniprot/B2R6L9 |
T444 | 497-502 | Protein | denotes | PD‐L1 | https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2 |
T453 | 587-600 | Protein | denotes | Interleukin 5 | https://www.uniprot.org/uniprot/Q9XT91|https://www.uniprot.org/uniprot/Q9MYM5|https://www.uniprot.org/uniprot/Q9ESI9|https://www.uniprot.org/uniprot/Q95J76|https://www.uniprot.org/uniprot/Q62575|https://www.uniprot.org/uniprot/Q28586|https://www.uniprot.org/uniprot/Q13840|https://www.uniprot.org/uniprot/Q08125|https://www.uniprot.org/uniprot/P52173|https://www.uniprot.org/uniprot/P48093|https://www.uniprot.org/uniprot/P46685|https://www.uniprot.org/uniprot/P05113|https://www.uniprot.org/uniprot/P04401|https://www.uniprot.org/uniprot/O77515|https://www.uniprot.org/uniprot/O62740|https://www.uniprot.org/uniprot/O08987|https://www.uniprot.org/uniprot/O02699|https://www.uniprot.org/uniprot/A9QWQ8 |
T471 | 779-784 | Protein | denotes | PD‐L1 | https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2 |
T480 | 909-939 | Protein | denotes | Angiopoietin‐related protein 3 | https://www.uniprot.org/uniprot/Q9Y5C1|https://www.uniprot.org/uniprot/Q9R182|https://www.uniprot.org/uniprot/B2RCW1|https://www.uniprot.org/uniprot/B1ALJ0|https://www.uniprot.org/uniprot/A0JLS0 |
T485 | 1021-1025 | Protein | denotes | CD19 | https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9 |
T494 | 1144-1159 | Protein | denotes | Interleukin 17A | https://www.uniprot.org/uniprot/Q95L56|https://www.uniprot.org/uniprot/Q687Y7|https://www.uniprot.org/uniprot/Q62386|https://www.uniprot.org/uniprot/Q61453|https://www.uniprot.org/uniprot/Q60I29|https://www.uniprot.org/uniprot/Q60971|https://www.uniprot.org/uniprot/Q5T2P0|https://www.uniprot.org/uniprot/Q16552 |
T502 | 1396-1423 | Protein | denotes | C chemokine receptor type 4 | https://www.uniprot.org/uniprot/Q9ULY7|https://www.uniprot.org/uniprot/Q9ULY6|https://www.uniprot.org/uniprot/Q8MJW8|https://www.uniprot.org/uniprot/Q14A03|https://www.uniprot.org/uniprot/P51680|https://www.uniprot.org/uniprot/P51679 |
T508 | 1425-1429 | Protein | denotes | CCR4 | https://www.uniprot.org/uniprot/Q9ULY7|https://www.uniprot.org/uniprot/Q9ULY6|https://www.uniprot.org/uniprot/Q8MJW8|https://www.uniprot.org/uniprot/Q14A03|https://www.uniprot.org/uniprot/P51680|https://www.uniprot.org/uniprot/P51679 |
T514 | 1568-1572 | Protein | denotes | CD19 | https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9 |
T523 | 1666-1670 | Protein | denotes | PD‐1 | https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3 |
T531 | 1760-1764 | Protein | denotes | CD20 | https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4 |
T538 | 1872-1876 | Protein | denotes | CD20 | https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4 |
T545 | 1974-1978 | Protein | denotes | PD‐1 | https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3 |
T553 | 2186-2192 | Protein | denotes | IL‐36R | https://www.uniprot.org/uniprot/Q9HB29|https://www.uniprot.org/uniprot/Q587I8|https://www.uniprot.org/uniprot/Q53TU8|https://www.uniprot.org/uniprot/Q45H74|https://www.uniprot.org/uniprot/Q13525|https://www.uniprot.org/uniprot/A4FU63 |
T559 | 2377-2381 | Protein | denotes | PD‐1 | https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3 |
T567 | 2606-2610 | Protein | denotes | PD‐1 | https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3 |
T575 | 2680-2684 | Protein | denotes | CD20 | https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4 |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T360 | 125-128 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T361 | 129-137 | Body_part | denotes | backbone | http://purl.org/sig/ont/fma/fma13478 |
T362 | 587-600 | Body_part | denotes | Interleukin 5 | http://purl.org/sig/ont/fma/fma264830 |
T363 | 587-598 | Body_part | denotes | Interleukin | http://purl.org/sig/ont/fma/fma86578 |
T364 | 688-691 | Body_part | denotes | ear | http://purl.org/sig/ont/fma/fma52780 |
T365 | 692-696 | Body_part | denotes | nose | http://purl.org/sig/ont/fma/fma46472 |
T366 | 697-703 | Body_part | denotes | throat | http://purl.org/sig/ont/fma/fma228738 |
T367 | 930-937 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T368 | 1088-1110 | Body_part | denotes | Central nervous system | http://purl.org/sig/ont/fma/fma55675 |
T369 | 1144-1155 | Body_part | denotes | Interleukin | http://purl.org/sig/ont/fma/fma86578 |
T370 | 1398-1407 | Body_part | denotes | chemokine | http://purl.org/sig/ont/fma/fma241981 |
T371 | 1493-1515 | Body_part | denotes | Central nervous system | http://purl.org/sig/ont/fma/fma55675 |
T372 | 2747-2769 | Body_part | denotes | Central nervous system | http://purl.org/sig/ont/fma/fma55675 |
T373 | 2791-2793 | Body_part | denotes | Ig | http://purl.org/sig/ont/fma/fma62871 |
T374 | 2795-2809 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-PD-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T13 | 688-691 | http://purl.obolibrary.org/obo/MAT_0000317 | denotes | ear |
T14 | 688-691 | http://purl.obolibrary.org/obo/MAT_0000233 | denotes | ear |
T15 | 688-691 | http://purl.obolibrary.org/obo/MAT_0000138 | denotes | ear |
T16 | 692-696 | http://purl.obolibrary.org/obo/MAT_0000139 | denotes | nose |
T17 | 1088-1110 | http://purl.obolibrary.org/obo/MAT_0000457 | denotes | Central nervous system |
T18 | 1096-1110 | http://purl.obolibrary.org/obo/MAT_0000026 | denotes | nervous system |
T19 | 1493-1515 | http://purl.obolibrary.org/obo/MAT_0000457 | denotes | Central nervous system |
T20 | 1501-1515 | http://purl.obolibrary.org/obo/MAT_0000026 | denotes | nervous system |
T21 | 2747-2769 | http://purl.obolibrary.org/obo/MAT_0000457 | denotes | Central nervous system |
T22 | 2755-2769 | http://purl.obolibrary.org/obo/MAT_0000026 | denotes | nervous system |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T27 | 688-713 | Disease | denotes | ear nose throat disorders | http://purl.obolibrary.org/obo/MONDO_0024623 |
T28 | 976-995 | Disease | denotes | Metabolic disorders | http://purl.obolibrary.org/obo/MONDO_0005066 |
T29 | 1221-1246 | Disease | denotes | musculoskeletal disorders | http://purl.obolibrary.org/obo/MONDO_0002081 |
T30 | 1707-1725 | Disease | denotes | Infectious disease | http://purl.obolibrary.org/obo/MONDO_0005550 |
T31 | 2015-2024 | Disease | denotes | Infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T32 | 2127-2150 | Disease | denotes | Hematological disorders | http://purl.obolibrary.org/obo/MONDO_0005570 |
T33 | 2333-2352 | Disease | denotes | Metabolic disorders | http://purl.obolibrary.org/obo/MONDO_0005066 |
T34 | 2916-2924 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T17 | 302-310 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T18 | 554-562 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T19 | 878-886 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T20 | 1112-1120 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T21 | 1359-1367 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T22 | 1517-1525 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T23 | 1635-1643 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T24 | 1727-1735 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T25 | 1839-1847 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T26 | 1939-1947 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T27 | 2026-2034 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T28 | 2564-2572 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T29 | 2647-2655 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T30 | 2771-2779 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T242 | 0-106 | Sentence | denotes | Table 4 Fc or hinge‐engineered monoclonal antibodies (mAbs) approved or in advanced clinical development. |
T243 | 107-216 | Sentence | denotes | mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage |
T244 | 217-321 | Sentence | denotes | Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III |
T245 | 322-482 | Sentence | denotes | Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III |
T246 | 483-572 | Sentence | denotes | Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed |
T247 | 573-766 | Sentence | denotes | Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed |
T248 | 767-896 | Sentence | denotes | Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed |
T249 | 897-1006 | Sentence | denotes | Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III |
T250 | 1007-1131 | Sentence | denotes | Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III |
T251 | 1132-1256 | Sentence | denotes | Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed |
T252 | 1257-1378 | Sentence | denotes | Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III |
T253 | 1379-1535 | Sentence | denotes | Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed |
T254 | 1536-1654 | Sentence | denotes | Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III |
T255 | 1655-1745 | Sentence | denotes | Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed |
T256 | 1746-1857 | Sentence | denotes | Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed |
T257 | 1858-1958 | Sentence | denotes | Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III |
T258 | 1959-2044 | Sentence | denotes | Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed |
T259 | 2045-2161 | Sentence | denotes | Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III |
T260 | 2162-2274 | Sentence | denotes | Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III |
T261 | 2275-2362 | Sentence | denotes | Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II |
T262 | 2363-2583 | Sentence | denotes | Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III |
T263 | 2584-2666 | Sentence | denotes | Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III |
T264 | 2667-2790 | Sentence | denotes | Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III |
T265 | 2791-2810 | Sentence | denotes | Ig, immunoglobulin. |
T266 | 2811-2958 | Sentence | denotes | John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. |
T267 | 2959-3141 | Sentence | denotes | It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T17 | 302-310 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T18 | 554-562 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T19 | 878-886 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T20 | 1112-1120 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T21 | 1359-1367 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T22 | 1517-1525 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T23 | 1635-1643 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T24 | 1727-1735 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T25 | 1839-1847 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T26 | 1939-1947 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T27 | 2026-2034 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T28 | 2564-2572 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T29 | 2647-2655 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T30 | 2771-2779 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |